Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.
van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, Macarthur RD; CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), and The International Network for Strategic Initiative in Global HIV Trials (INSIGHT). van den Berg-Wolf M, et al. Among authors: novak rm. HIV Clin Trials. 2008 Sep-Oct;9(5):324-36. doi: 10.1310/hct0905-324. HIV Clin Trials. 2008. PMID: 18977721 Clinical Trial.
The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial.
MacArthur RD, Chen L, Mayers DL, Besch CL, Novak R, van den Berg-Wolf M, Yurik T, Peng G, Schmetter B, Brizz B, Abrams D; CPCRA 058 FIRST Trial Study Team. MacArthur RD, et al. Control Clin Trials. 2001 Apr;22(2):176-90. doi: 10.1016/s0197-2456(01)00111-8. Control Clin Trials. 2001. PMID: 11306155 Clinical Trial.
Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.
Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M; Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team. Novak RM, et al. Clin Infect Dis. 2005 Feb 1;40(3):468-74. doi: 10.1086/427212. Epub 2005 Jan 10. Clin Infect Dis. 2005. PMID: 15668873 Clinical Trial.
Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.
MacArthur RD, Chen L, Peng G, Novak RM, van den Berg-Wolf M, Kozal M, Besch L, Yurik T, Schmetter B, Henley C, Dehlinger M; CPRCA 058 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. MacArthur RD, et al. Among authors: novak rm. HIV Clin Trials. 2004 Nov-Dec;5(6):361-70. doi: 10.1310/WEQG-QTHL-DL3X-FTXC. HIV Clin Trials. 2004. PMID: 15682349 Clinical Trial.
A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M; CPCRA 058 Study Team; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). MacArthur RD, et al. Among authors: novak rm. Lancet. 2006 Dec 16;368(9553):2125-35. doi: 10.1016/S0140-6736(06)69861-9. Lancet. 2006. PMID: 17174704 Clinical Trial.
The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies.
Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf Mv, Peng G, Xiang Y, Baxter JD, Uy J, Telzak EE, Novak RM; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Kozal MJ, et al. Among authors: novak rm. HIV Clin Trials. 2007 Nov-Dec;8(6):357-70. doi: 10.1310/hct0806-357. HIV Clin Trials. 2007. PMID: 18042501 Clinical Trial.
Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ; Terry Beirn Community Programs for Clinical Research on AIDS. Simen BB, et al. Among authors: novak rm. J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736. J Infect Dis. 2009. PMID: 19210162 Clinical Trial.
Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.
Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, Bohjanen PR, Novak RM, Neaton JD, Sereti I; INSIGHT Study Group. Boulware DR, et al. Among authors: novak rm. J Infect Dis. 2011 Jun 1;203(11):1637-46. doi: 10.1093/infdis/jir134. J Infect Dis. 2011. PMID: 21592994 Free PMC article. Clinical Trial.
201 results